Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

L Gately^{1

2}, C Mesía³, J M Sepúlveda⁴, S Del Barco⁵, E Pineda⁶, R Gironés⁷, J Fuster⁸, W Hong⁹, M Dumas⁹, S Gill¹⁰, L M Navarro¹¹, A Herrero¹², A Dowling¹³, R de Las Peñas¹⁴, M A Vaz¹⁵, M Alonso¹⁶, Z Lwin¹⁷, R Harrup¹⁸, S Peralta¹⁹, A Long²⁰, P Perez-Segura²¹, E Ahern²², C O Garate²³, M Wong²⁴, R Campbell²⁵, K Cuff²⁶, R Jennens²⁷, O Gallego²⁸, C Underhill²⁹, M Martinez-Garcia³⁰, M Covela³¹, A Cooper³², S Brown³³, M Rosenthal³⁴, J Torres³⁵, I M Collins³⁶, P Gibbs⁹, C Balana^{37

38}

Affiliations

¹ Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. gately.l@wehi.edu.au.
² Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia. gately.l@wehi.edu.au.
³ Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain.
⁴ Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
⁵ Medical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain.
⁶ Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain.
⁷ Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain.
⁸ Medical Oncology Service, Hospital Son Espases, Palma de Mallorca, Spain.
⁹ Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
¹⁰ Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
¹¹ Medical Oncology Service, Hospital de Salamanca, Salamanca, Spain.
¹² Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain.
¹³ Department of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
¹⁴ Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain.
¹⁵ Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain.
¹⁶ Medical Oncology Service, Hospital Virgen del Rocio, Seville, Spain.
¹⁷ Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
¹⁸ Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia.
¹⁹ Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain.
²⁰ Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
²¹ Medical Oncology Service, Hospital Clinico San Carlos, Madrid, Spain.
²² Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia.
²³ Medical Oncology Service, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.
²⁴ Department of Medical Oncology, Westmead Hospital, Westmead, NSW, Australia.
²⁵ Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia.
²⁶ Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
²⁷ Department of Medical Oncology, Epworth Health, Richmond, VIC, Australia.
²⁸ Medical Oncology Service, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
²⁹ Department of Medical Oncology, Border Medical Oncology, East Albury, NSW, Australia.
³⁰ Medical Oncology Service, Hospital del Mar, Barcelona, Spain.
³¹ Medical Oncology Service, Hospital Lucus Augusti, Lugo, Spain.
³² Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia.
³³ Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia.
³⁴ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³⁵ Department of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia.
³⁶ Department of Medical Oncology, South West Regional Cancer Centre, Geelong, VIC, Australia.
³⁷ Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain.
³⁸ Badalona Applied Research Group in Oncology (B-ARGO), Institut Investigació Germans Trias I Pujol (IGTP), Badalona, Spain.

PMID: 38289531
DOI: 10.1007/s11060-024-04581-x

Published Erratum

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

L Gately et al. J Neurooncol. 2024 Feb.

. 2024 Feb;166(3):417-418.

doi: 10.1007/s11060-024-04581-x.

Authors

Affiliations

¹ Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. gately.l@wehi.edu.au.
² Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia. gately.l@wehi.edu.au.
³ Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain.
⁴ Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
⁵ Medical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain.
⁶ Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain.
⁷ Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain.
⁸ Medical Oncology Service, Hospital Son Espases, Palma de Mallorca, Spain.
⁹ Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
¹⁰ Department of Medical Oncology, Alfred Health, Melbourne, VIC, Australia.
¹¹ Medical Oncology Service, Hospital de Salamanca, Salamanca, Spain.
¹² Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain.
¹³ Department of Medical Oncology, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
¹⁴ Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain.
¹⁵ Medical Oncology Service, Hospital Ramón y Cajal, Madrid, Spain.
¹⁶ Medical Oncology Service, Hospital Virgen del Rocio, Seville, Spain.
¹⁷ Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
¹⁸ Department of Medical Oncology, Royal Hobart Hospital, Hobart, TAS, Australia.
¹⁹ Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain.
²⁰ Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
²¹ Medical Oncology Service, Hospital Clinico San Carlos, Madrid, Spain.
²² Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia.
²³ Medical Oncology Service, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.
²⁴ Department of Medical Oncology, Westmead Hospital, Westmead, NSW, Australia.
²⁵ Department of Medical Oncology, Bendigo Health, Bendigo, VIC, Australia.
²⁶ Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia.
²⁷ Department of Medical Oncology, Epworth Health, Richmond, VIC, Australia.
²⁸ Medical Oncology Service, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
²⁹ Department of Medical Oncology, Border Medical Oncology, East Albury, NSW, Australia.
³⁰ Medical Oncology Service, Hospital del Mar, Barcelona, Spain.
³¹ Medical Oncology Service, Hospital Lucus Augusti, Lugo, Spain.
³² Department of Medical Oncology, Liverpool Hospital, Liverpool, NSW, Australia.
³³ Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC, Australia.
³⁴ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³⁵ Department of Medical Oncology, Goulburn Valley Health, Shepparton, VIC, Australia.
³⁶ Department of Medical Oncology, South West Regional Cancer Centre, Geelong, VIC, Australia.
³⁷ Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain.
³⁸ Badalona Applied Research Group in Oncology (B-ARGO), Institut Investigació Germans Trias I Pujol (IGTP), Badalona, Spain.

PMID: 38289531
DOI: 10.1007/s11060-024-04581-x

No abstract available

PubMed Disclaimer

Erratum for

A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.
Gately L, Mesía C, Sepúlveda JM, Del Barco S, Pineda E, Gironés R, Fuster J, Hong W, Dumas M, Gill S, Navarro LM, Herrero A, Dowling A, de Las Peñas R, Vaz MA, Alonso M, Lwin Z, Harrup R, Peralta S, Long A, Perez-Segura P, Ahern E, Garate CO, Wong M, Campbell R, Cuff K, Jennens R, Gallego O, Underhill C, Martinez-Garcia M, Covela M, Cooper A, Brown S, Rosenthal M, Torres J, Collins IM, Gibbs P, Balana C. Gately L, et al. J Neurooncol. 2024 Feb;166(3):407-415. doi: 10.1007/s11060-023-04513-1. Epub 2023 Dec 28. J Neurooncol. 2024. PMID: 38153582 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

Affiliations

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources